Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 686

1.

Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study.

McKenzie R, Bourgeois AL, Frech SA, Flyer DC, Bloom A, Kazempour K, Glenn GM.

Vaccine. 2007 May 4;25(18):3684-91. Epub 2007 Jan 23.

PMID:
17313998
2.

Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum.

Glenn GM, Villar CP, Flyer DC, Bourgeois AL, McKenzie R, Lavker RM, Frech SA.

Infect Immun. 2007 May;75(5):2163-70. Epub 2007 Jan 29.

3.

Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.

Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HL, Maxwell R, Paredes-Paredes M, Glenn GM, Dewasthaly S, Stablein DM, Jiang ZD, DuPont HL.

Lancet Infect Dis. 2014 Mar;14(3):197-204. doi: 10.1016/S1473-3099(13)70297-4. Epub 2013 Nov 29.

PMID:
24291168
5.

Construction and phase I clinical evaluation of the safety and immunogenicity of a candidate enterotoxigenic Escherichia coli vaccine strain expressing colonization factor antigen CFA/I.

Turner AK, Beavis JC, Stephens JC, Greenwood J, Gewert C, Thomas N, Deary A, Casula G, Daley A, Kelly P, Randall R, Darsley MJ.

Infect Immun. 2006 Feb;74(2):1062-71.

6.

The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine.

Jones FR, Hall ER, Tribble D, Savarino SJ, Cassels FJ, Porter C, Meza R, Nunez G, Espinoza N, Salazar M, Luckett R, Scott D.

Vaccine. 2006 May 1;24(18):3786-92. Epub 2005 Aug 30.

PMID:
16343702
7.

Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.

Lundgren A, Bourgeois L, Carlin N, Clements J, Gustafsson B, Hartford M, Holmgren J, Petzold M, Walker R, Svennerholm AM.

Vaccine. 2014 Dec 12;32(52):7077-84. doi: 10.1016/j.vaccine.2014.10.069. Epub 2014 Nov 5.

8.

A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC.

McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, Finucane M, Sack RB, Hall E, Bourgeois AL.

Vaccine. 2008 Aug 26;26(36):4731-9. doi: 10.1016/j.vaccine.2008.06.064. Epub 2008 Jul 9.

PMID:
18602960
9.

Doxycycline prophylaxis of travelers' diarrhea in Honduras, an area where resistance to doxycycline is common among enterotoxigenic Escherichia coli.

Sack RB, Santosham M, Froehlich JL, Medina C, Orskov F, Orskov I.

Am J Trop Med Hyg. 1984 May;33(3):460-6.

PMID:
6375407
10.

Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.

Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM.

Vaccine. 2013 May 7;31(20):2457-64. doi: 10.1016/j.vaccine.2013.03.027. Epub 2013 Mar 27.

11.

Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen.

Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, van Hamont JE, Newcomer RL, Davachi MA, Taylor DN, McQueen CE.

Vaccine. 2003 Jan 17;21(5-6):341-6.

PMID:
12531630
13.

Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers.

Carpenter CM, Hall ER, Randall R, McKenzie R, Cassels F, Diaz N, Thomas N, Bedford P, Darsley M, Gewert C, Howard C, Sack RB, Sack DA, Chang HS, Gomes G, Bourgeois AL.

Vaccine. 2006 May 1;24(18):3709-18. Epub 2005 Jul 26.

PMID:
16153753
14.

Development of pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccine against enterotoxigenic Escherichia coli in Egypt: application of an evidence-based method.

Clemens J, Savarino S, Abu-Elyazeed R, Safwat M, Rao M, Wierzba T, Svennerholm AM, Holmgren J, Frenck R, Park E, Naficy A.

J Infect Dis. 2004 Jun 15;189(12):2299-307. Epub 2004 May 25.

PMID:
15181579
15.

Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.

Leyten EM, Soonawala D, Schultsz C, Herzog C, Ligthelm RJ, Wijnands S, Visser LG.

Vaccine. 2005 Oct 17;23(43):5120-6.

PMID:
15982790
16.

Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.

McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA.

Infect Immun. 2006 Feb;74(2):994-1000.

17.

Transcutaneous immunization using colonization factor and heat-labile enterotoxin induces correlates of protective immunity for enterotoxigenic Escherichia coli.

Yu J, Cassels F, Scharton-Kersten T, Hammond SA, Hartman A, Angov E, Corthésy B, Alving C, Glenn G.

Infect Immun. 2002 Mar;70(3):1056-68.

18.

Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.

Güereña-Burgueño F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova GV, Alving CR, Glenn GM.

Infect Immun. 2002 Apr;70(4):1874-80.

20.

Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial.

Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR, et al.

J Infect Dis. 1988 Aug;158(2):372-7.

PMID:
3042876

Supplemental Content

Support Center